

**BIOCON GROUP**

**FACT SHEET**

**September 2011**

**H1 FY 2012 vs. H1 FY 2011**

**Q2 FY 2012 vs. Q2 FY 2011**

<b>BIOCON LIMITED (CONSOLIDATED) UNAUDITED BALANCE SHEET</b>		
	<i>(Rs. Crores)</i>	
	<b>September-11</b>	<b>March -11*</b>
<b><u>SOURCES OF FUNDS</u></b>		
Share Capital	100	100
Reserves & Surplus	2,107	1,933
<b>Total Shareholder's Funds</b>	<b>2,207</b>	<b>2,033</b>
<b>Deferred Tax Liability</b>	<b>41</b>	<b>50</b>
<b>Minority Interest</b>	<b>-</b>	<b>38</b>
Secured Loans	214	204
Unsecured Loans	119	130
	<b>333</b>	<b>334</b>
<b>TOTAL</b>	<b>2,581</b>	<b>2,454</b>
<b><u>APPLICATION OF FUNDS</u></b>		
<b>Fixed Assets (Net)</b>	<b>1,493</b>	<b>1,356</b>
<b>Intangible Assets</b>	<b>238</b>	<b>234</b>
<b>Investments - Liquid Funds</b>	<b>467</b>	<b>400</b>
<b>Investments - Others</b>	<b>64</b>	<b>61</b>
Inventories	343	414
Sundry debtors	506	512
Cash and bank balances	319	441
Loans and advances	174	136
<b>Total Current Assets</b>	<b>1,342</b>	<b>1,503</b>
<b>Less: Current liabilities</b>	<b>1,023</b>	<b>1,100</b>
<b>Net Current assets</b>	<b>318</b>	<b>403</b>
<b>TOTAL</b>	<b>2,581</b>	<b>2,454</b>
* including Axicorp		

<b>BIOCON LIMITED (CONSOLIDATED) UNAUDITED PROFIT &amp; LOSS STATEMENT</b>			
			<i>(Rs. Crores)</i>
Particulars	Q2 FY 12	Q2 FY 11	Variance
<b><u>INCOME</u></b>			
Biopharmaceuticals	351	294	19%
Biopharmaceuticals - Branded formulations	64	49	35%
<b>Total Biopharmaceuticals</b>	<b>415</b>	<b>343</b>	<b>21%</b>
Contract research	93	78	19%
<b>Total Sales</b>	<b>508</b>	<b>421</b>	<b>21%</b>
Other income	16	7	116%
<b>Total Revenue</b>	<b>524</b>	<b>428</b>	<b>23%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power Costs	237	189	25%
Staff costs	72	52	38%
Research & Development	31	20	55%
Other Expenses	35	30	19%
<b>Manufacturing, staff &amp; other expenses</b>	<b>375</b>	<b>291</b>	<b>29%</b>
<b>PBDIT /EBITDA</b>	<b>149</b>	<b>137</b>	<b>9%</b>
Interest and finance charges	2	6	-68%
Depreciation & Amortisation	42	38	13%
<b>PBT</b>	<b>105</b>	<b>93</b>	<b>12%</b>
Taxes	19	11	69%
<b>NET PROFIT (PAT) WITHOUT AXICORP</b>	<b>86</b>	<b>82</b>	<b>5%</b>
Profit from discontinued (AxiCorp) Operations, net	-	7	
<b>NET PROFIT FOR THE PERIOD</b>	<b>86</b>	<b>89</b>	<b>-4%</b>
<b>EPS Rs.</b>	<b>4.3</b>	<b>4.5</b>	
<i>Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers</i>			
<i>Biopharmaceuticals Income includes Licensing development fees of Rs 37 crores in Q2 FY 2012 vs. Licensing Income of Rs.23 crores in Q2 FY 2011.</i>			

<b>BIOCON LIMITED (CONSOLIDATED) UNAUDITED PROFIT &amp; LOSS STATEMENT</b>			
			<i>(Rs. Crores)</i>
Particulars	H1 FY 12	H1 FY 11	Variance
<b><u>INCOME</u></b>			
Biopharmaceuticals	648	583	11%
Biopharmaceuticals - Branded formulations	122	88	37%
<b>Total Biopharmaceuticals</b>	<b>770</b>	<b>671</b>	<b>15%</b>
Contract research	180	150	20%
<b>Total Sales</b>	<b>950</b>	<b>821</b>	<b>16%</b>
Other income	28	16	81%
<b>Total Revenue</b>	<b>978</b>	<b>837</b>	<b>17%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power Costs	449	384	17%
Staff costs	137	103	33%
Research & Development	51	41	24%
Other Expenses	59	54	11%
<b>Manufacturing, staff &amp; other expenses</b>	<b>696</b>	<b>582</b>	<b>20%</b>
<b>PBDIT /EBITDA</b>	<b>282</b>	<b>255</b>	<b>11%</b>
Interest and finance charges	8	13	-39%
Depreciation & Amortisation	88	74	19%
<b>PBT</b>	<b>186</b>	<b>168</b>	<b>11%</b>
Taxes	30	21	45%
<b>NET PROFIT (PAT) WITHOUT AXICORP</b>	<b>156</b>	<b>147</b>	<b>6%</b>
Profit from discontinued (AxiCorp) Operations, net	-	19	
<b>NET PROFIT FOR THE PERIOD</b>	<b>156</b>	<b>166</b>	<b>-6%</b>
<b>EPS Rs.</b>	<b>7.8</b>	<b>8.3</b>	
<p><i>Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers</i></p> <p><i>Biopharmaceuticals Income includes Licensing development fees of Rs 51 crores in H1 FY 2012 vs. Licensing Income of Rs.44 crores in H1 FY 2011.</i></p>			